

1/10

SEQUENCE LISTING

<110> Reinherz, Ellis L.
 Freund, Christian
 Li, Jing
 Nishizawa, Kazuhisa
 Wagner, Gerhard

<120> Cloning and Characterization of a CD2 Binding Protein (CD2BP2)

```
<130> 1062.1021-004
<140> 09/873,106
<141> 2001-06-01
<150> US 60/111,007
<151> 1998-12-04
<150> US 60/115,647
<151> 1999-01-13
<150> PCT/US99/26993
<151> 1999-11-15
<160> 25
<170> FastSEQ for Windows Version 4.0
<210> 1
<211> 1299
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (121) ... (1143)
agtectette egggtgatgg eggegggtge eeeggatgta geeetggege aageatetet 60
tettttttee acctegeett eegeggatte eeagettgag aaacacetet ttgeceegte 120
atg cca aag agg aaa gtg acc ttc caa ggc gtg gga gat gag gag gat
Met Pro Lys Arg Lys Val Thr Phe Gln Gly Val Gly Asp Glu Glu Asp
```

gag gat gaa atc att gtc ccc aag aag ctg gtg gac cct gtg gct

Glu Asp Glu Ile Ile Val Pro Lys Lys Leu Val Asp Pro Val Ala

ggg tca ggg ggt cct ggg agc cgc ttt aaa ggc aaa cac tct ttg gat Gly Ser Gly Gly Pro Gly Ser Arg Phe Lys Gly Lys His Ser Leu Asp 216

agc Ser	gat Asp 50	gag Glu	gag Glu	gag Glu	gat Asp	gat Asp 55	gat Asp	gat Asp	ggg Gly	ggg ggg	tcc Ser 60	agc Ser	aaa Lys	tat Tyr	gac Asp	312
atc Ile 65	ttg Leu	gcc Ala	tca Ser	gag Glu	gat Asp 70	gta Val	gaa Glu	ggt Gly	cag Gln	gag Glu 75	gca Ala	gcc Ala	aca Thr	ctc L e u	ccc Pro 80	360
								ccc Pro								408
gag Glu	gaa Glu	ggc Gly	cac His 100	ttt Phe	gat Asp	gcc Ala	gat Asp	ggc Gly 105	aac Asn	tac Tyr	ttc Phe	ctg Leu	aac Asn 110	cgg Arg	gat Asp	456
								gac Asp								504
								cag Gln								552
								agt Ser								600
								gag Glu								648
								aaa Lys 185								696
								cgg Arg								744
								gtg Val								792
ttg Leu 225	gct Ala	atg Met	cgt Arg	ctg Leu	aag Lys 230	ggt Gly	ttg Leu	gly ggg	tgt Cys	cag Gln 235	acc Thr	cta Leu	gga Gly	ccc Pro	cac His 240	840
aat Asn	ccc Pro	aca Thr	ccc Pro	cca Pro 245	ccc Pro	tcc Ser	ctg Leu	gac Asp	atg Met 250	ttc Phe	gct Ala	gag Glu	gag Glu	ttg Leu 255	gcg Ala	888
gag Glu	gag Glu	gaa Glu	ctg Leu 260	gag Glu	acc Thr	cca Pro	acc Thr	cct Pro 265	acc Thr	cag Gln	aga Arg	gga Gly	gaa Glu 270	gca Ala	gag Glu	936

Ser Arg Gly Asp Gly Leu Val Asp Val Met Trp Glu Tyr Lys Trp Glu 275 280 285	984
Asn Thr Gly Asp Ala Glu Leu Tyr Gly Pro Phe Thr Ser Ala Gln Met 290	1032
cag acc tgg gtg agt gaa ggc tac ttc ccg gac ggt gtt tat tgc cgg Gln Thr Trp Val Ser Glu Gly Tyr Phe Pro Asp Gly Val Tyr Cys Arg 305 310 315 320	1080
aag ctg gac ccc cct ggt ggt cag ttc tac aac tcc aaa cgc att gac Lys Leu Asp Pro Pro Gly Gly Gln Phe Tyr Asn Ser Lys Arg Ile Asp 325 330 335	1128
ttt gac ctc tac acc tgagcctgct ggggggcccag tttggtgggc ccttctttcc Phe Asp Leu Tyr Thr 340	1183
tggactttgt ggaggaggca ccaagtgtct caggcagcga ggaaattgga ggccattttt cagtcaattt ccctttccca ataaaagcct tagttgtgta aaaaaaaaaa	1243 1299
<210> 2 <211> 341 <212> PRT <213> Homo sapiens	
<400> 2	
Met Pro Lys Arg Lys Val Thr Phe Gln Gly Val Gly Asp Glu Glu Asp 1 10 15	
Glu Asp Glu Ile Ile Val Pro Lys Lys Leu Val Asp Pro Val Ala 20 25 30	
Gly Ser Gly Gly Pro Gly Ser Arg Phe Lys Gly Lys His Ser Leu Asp	
2E 40 45	
35 40 45 Ser Asp Glu Glu Glu Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp	
Ser Asp Glu Glu Glu Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp 50 55 60 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro	
Ser Asp Glu Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp 50 55 60 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro 65 70 75 80 Ser Glu Gly Gly Gly Arg Ile Thr Pro Phe Asn Leu Gln Glu Glu Met	
Ser Asp Glu Glu Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp 50 55 60 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro 65 70 75 80 Ser Glu Gly Gly Gly Arg Ile Thr Pro Phe Asn Leu Gln Glu Glu Met 85 90 95 Glu Glu Gly His Phe Asp Ala Asp Gly Asn Tyr Phe Leu Asn Arg Asp	
Ser Asp Glu Glu Glu Glu Asp Asp Asp Asp Gly Gly Gly Ser Ser Lys Tyr Asp 50 55 60 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro 65 70 75 80 Ser Glu Gly Gly Gly Arg Ile Thr Pro Phe Asn Leu Gln Glu Glu Met 85 90 95 Glu Glu Gly His Phe Asp Ala Asp Gly Asn Tyr Phe Leu Asn Arg Asp 105 100 105 110 Ala Gln Ile Arg Asp Ser Trp Leu Asp Asn Ile Asp Trp Val Lys Ile	
Ser Asp Glu Glu Glu Glu Asp Asp Asp Asp Gly Gly Gly Ser Ser Lys Tyr Asp 50 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro 65 Ser Glu Gly Gly Gly Arg Ile Thr Pro Phe Asn Leu Gln Glu Glu Met 85 Glu Glu Gly His Phe Asp Ala Asp Gly Asn Tyr Phe Leu Asn Arg Asp 100 Ala Gln Ile Arg Asp Ser Trp Leu Asp Asn Ile Asp Trp Val Lys Ile 115 Arg Glu Arg Pro Pro Gly Gln Arg Gln Ala Ser Asp Ser Glu Glu Glu Glu	
Ser Asp Glu Glu Glu Glu Asp Asp Asp Asp Gly Gly Gly Ser Ser Lys Tyr Asp 50 55 60 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro 65 70 75 80 Ser Glu Gly Gly Gly Arg Ile Thr Pro Phe Asn Leu Gln Glu Glu Met 85 90 95 Glu Glu Gly His Phe Asp Ala Asp Gly Asn Tyr Phe Leu Asn Arg Asp 100 105 110 Ala Gln Ile Arg Asp Ser Trp Leu Asp Asn Ile Asp Trp Val Lys Ile 115 120 Arg Glu Arg Pro Pro Gly Gln Arg Gln Ala Ser Asp Ser Glu Glu Glu Glu 130 135 Asp Ser Leu Gly Gln Thr Ser Met Ser Ala Gln Ala Leu Leu Glu Gly	
Ser Asp Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp Ile Leu Ala Ser Glu Asp Val Glu Gly Glu Ala Ala Ala Thr Leu Pro Pro Asp Glu Ala Ala Ala Thr Leu Pro Pro Asp Asp Inch Pro Asp	
Ser Asp Glu Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp Ile Leu Ala Ser Glu Asp Val Glu Gly Glu Ala Ala Ala Thr Leu Pro Pro Asp Glu Ala Ala Ala Thr Leu Pro Pro Asp Asp Incompany Incompany<	
Ser Asp Glu Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp Ile Leu Ala Ser Glu Asp Val Glu Gly Glu Ala Ala Ala Thr Leu Pro Pro Asp Glu Ala A	
Ser Asp Glu Glu Asp Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp Ile Leu Ala Ser Glu Asp Val Glu Gly Glu Ala Ala Ala Thr Leu Pro Pro Asp Glu Ala A	

<212> PRT

Leu Ala Met Arg Leu Lys Gly Leu Gly Cys Gln Thr Leu Gly Pro His 230 235 Asn Pro Thr Pro Pro Pro Ser Leu Asp Met Phe Ala Glu Glu Leu Ala 245 250 Glu Glu Glu Leu Glu Thr Pro Thr Pro Thr Gln Arg Gly Glu Ala Glu 260 265 270 Ser Arg Gly Asp Gly Leu Val Asp Val Met Trp Glu Tyr Lys Trp Glu 275 280 285 Asn Thr Gly Asp Ala Glu Leu Tyr Gly Pro Phe Thr Ser Ala Gln Met 295 300 Gln Thr Trp Val Ser Glu Gly Tyr Phe Pro Asp Gly Val Tyr Cys Arg 310 315 Lys Leu Asp Pro Pro Gly Gly Gln Phe Tyr Asn Ser Lys Arg Ile Asp 325 330 Phe Asp Leu Tyr Thr <210> 3 <211> 26 <212> PRT <213> Homo sapiens <400> 3 Gly Asp Ala Glu Leu Tyr Gly Pro Phe Thr Ser Ala Gln Met Gln Thr Trp Val Ser Glu Gly Tyr Phe Pro Asp Gly 20 <210> 4 <211> 27 <212> PRT <213> Caenorhabditis elegans <400> 4 Gly Pro Asp Ser Glu Lys Tyr Gly Pro Tyr Met Ser Lys Asp Met Leu 10 1 5 Phe Trp Leu Gln Ala Gly Tyr Phe Asn Asp Gly <210> 5 <211> 27 <212> PRT <213> Caenorhabditis elegans Asp Pro Thr Glu Thr Arg Arg Gly Pro Phe Pro Lys Asp Gln Met Asn Val Trp Phe Lys Ala Gly Tyr Phe Thr Asp Glu 20 <210> 6 <211> 27

```
<213> Caenorhabditis elegans
<400> 6
Asp Asp Arg Gly Thr Val Gln Gly Pro Tyr Gly Ala Ser Thr Val Leu
                                   10
Asp Trp Tyr Gln Lys Gly Tyr Phe Ser Asp Asn
            20
<210> 7
<211> 29
<212> PRT
<213> Saccharomyces cerevisiae
<400> 7
Asp Thr Gln Gly Gln Ile His Gly Pro Phe Thr Thr Gln Met Met Ser
1
                                    10
Gln Trp Tyr Ile Gly Gly Leu Glu Tyr Phe Ala Ser Thr
                                25
<210> 8
<211> 27
<212> PRT
<213> Saccharomyces cerevisiae
<400> 8
Asp Ser Asn Gly Asn Ile Gln Gly Pro Phe Gly Thr Asn Asn Met Ser
Gln Trp Tyr Gln Gly Gly Tyr Phe Thr Pro Thr
<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence
<223> Motif in CD2 binding region of CD2BP2
<221> VARIANT
<222> 1,2,4,5,6,7,9,10,11,12,13,14,15
<223> Xaa = Any Amino Acid
<221> VARIANT
<222> 3
<223> Xaa can be Tyr or Phe
<221> VARIANT
<222> 8
<223> Xaa can be Met or Val
```

```
<400> 9
Gly Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Xaa Gly Tyr
                                   10
1
Phe
<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> CD2BP2 binding region
<400> 10
Pro Pro Pro Gly His Arg
1
               5
<210> 11
<211> 70
<212> PRT
<213> Homo sapiens
Pro Pro Pro Pro Gly His Arg Ser Gln Ala Pro Ser His Arg Pro
                                   10
Pro Pro Pro Gly His Arg Val Gln His Gln Pro Gln Lys Arg Pro Pro
                              25
Ala Pro Ser Gly Thr Gln Val His Gln Gln Lys Gly Pro Pro Leu Pro
                                              45
                          40
Arg Pro Arg Val Gln Pro Lys Pro Pro His Gly Ala Ala Glu Asn Ser
Leu Ser Pro Ser Ser Asn
                   70
<210> 12
<211> 8
<212> DNA
<213> Artificial Sequence
<223> Kozak consensus sequence
<400> 12
ccgccacc
<210> 13
<211> 24
<212> DNA
<213> Artificial Sequence
<223> Flag Epitope
```

7/10

```
<400> 13
gactacaagg acgacgatga caag
<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Flag Epitope
<400> 14
Asp Tyr Lys Asp Asp Asp Lys
<210> 15
<211> 31
<212> PRT
<213> Gallus gallus
<220>
<223> Flag Epitope
<400> 15
Trp Tyr Tyr Lys Asp Pro Gln Gly Glu Ile Gln Gly Pro Phe Ser Asn
                                    10
Gln Glu Met Ala Glu Trp Phe Gln Ala Gly Tyr Phe Thr Met Ser
<210> 16
<211> 38
<212> PRT
<213> Drosophila melanogaster
<223> Flag Epitope
<400> 16
Glu Val Thr Trp Glu Phe Lys Trp Ser Gln Asp Glu Thr Asp Ile Gln
                                    10
Gly Pro Phe Ser Thr Glu Lys Met Leu Lys Trp Ser Gln Glu Asn Thr
            20
Arg Tyr Phe Lys Asn Gly
       35
<210> 17
<211> 34
<212> PRT
<213> Leishmania major
<220>
<223> Flag Epitope
```

```
<400> 17
Val Trp Met Met Arg Trp Lys Ala Lys Pro Thr Val Gln His Gly Pro
            5
                                    10
Phe Thr Asp Asp Ala Ile Gln Gln Trp Gly Arg Asp Gly Tyr Phe Gly
Lys Lys
<210> 18
<211> 36
<212> PRT
<213> Caenorhabditis elegans
<220>
<223> Flag Epitope
<400> 18
Val Ile Asp Thr Lys Trp His Tyr Leu Gly Pro Asp Ser Glu Lys Tyr
                                    10
Gly Pro Tyr Met Ser Lys Asp Met Leu Phe Trp Leu Gln Ala Gly Tyr
                                25
Phe Asn Asp Gly
        35
<210> 19
<211> 35
<212> PRT
<213> Caenorhabditis elegans
<220>
<223> Flag Epitope
Val Glu Ser Ser Trp Arg Tyr Ile Asp Thr Gln Gly Gln Ile His Gly
1
                                    10
Pro Phe Thr Ile Gln Met Met Ser Gln Trp Tyr Ile Gly Gly Tyr Phe
Ala Ser Thr
        35
<210> 20
<211> 35
<212> PRT
<213> Saccharomyces cerevisiae
<220>
<223> Flag Epitope
<400> 20
Ile Glu Ser Gln Trp Lys Tyr Ile Asp Ser Asn Gly Asn Ile Gln Gly
                5
                                    10
Pro Phe Gly Thr Asn Asn Met Ser Gln Trp Tyr Gln Gly Gly Tyr Phe
```

```
Thr Pro Thr
       35
<210> 21
<211> 31
<212> PRT
<213> Saccharomces pombe
<220>
<223> Flag Epitope
<400> 21
Trp Leu Tyr Lys Asp Pro Gln Asn Asn Val Gln Gly Pro Phe Thr Gly
1 5
                    10
Val Asp Met His Gln Trp Tyr Arg Ala Gly Tyr Phe Pro Leu Gly
           20
                               25
<210> 22
<211> 21
<212> PRT
<213> Homo sapiens
<220>
<223> Flag Epitope
<400> 22
Pro Pro Pro Pro Gly His Arg Ser Gln Ala Pro Ser His Arg Pro Pro
Pro Pro Gly His Arg
           20
<210> 23
<211> 62
<212> PRT
<213> Homo sapiens
<220>
<223> Flag Epitope
<400> 23
Asp Val Met Trp Glu Tyr Lys Trp Glu Asn Thr Gly Asp Ala Glu Leu
Tyr Gly Pro Phe Thr Ser Ala Gln Met Gln Thr Trp Val Ser Glu Gly
       20
                              25
Tyr Phe Pro Asp Gly Val Tyr Cys Arg Lys Leu Asp Pro Pro Gly Gly
                          40
Gln Phe Tyr Asn Ser Lys Arg Ile Asp Phe Asp Leu Tyr Thr
<210> 24
<211> 31
<212> PRT
<213> Homo sapiens
```

10/10

<223> Flag Epitope

Application No.: 09/873,106

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

DE JOSE	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
CATEMY & TRADER	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
\boxtimes	7. Other: Sequences which lack a SEQ ID NO: tag are disclosed on pages 16, 19 and 20 of the specification. See attached Office Action
Ар	plicant Must Provide:ONLY IF THE CRF DOES NOT CONTAIN SAID SEQUENCE.
×	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X	An <i>i</i> nitial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentln Software Program Support (SIRA)
	Technical Assistance703-287-0200 To Purchase PatentIn Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE